Skip to main content

Table 1 Patient characteristics

From: Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV

Patient Number* (Age, sex)

ART regimen

Duration (months)

CD4+ T-cell count (cells/μL)

  

Total time under treatment

Time with HIV-1 RNA < 50 copies/mL

Time in treatment after IVIG administration

Current

Nadir

1 (65,M)

ABC+3TC+EFV

103

96.1

24.3

470

180

2 (53,M)

TDF+FTC+EFV

147.6

105.3

21.6

790

200

3 (35,M)

ABC+ZDV+3TC+LPV/r

76.6

73.6

20.5

180

20

4 (36,F)

ABC+3TC+ATV/r

76

71

21.5

430

50

5 (58,M)

3TC+ABC+LPV/r

145.6

84.3

11.7

150

40

6 (36,M)

ZDV+3TC+EFV

132.7

48.3

12.4

240

120

7 (43,M)

TDF+FTC+LPV/r

99

32

10.6

550

40

8 (45,M)

3TC+ABC+NVP

95.4

87.2

12.1

310

30

9 (43,M)

TDF+FTC+ATV/r

92.6

79.3

12.3

640

90

Median

 

99

79.3

12.4

430**

50

C1 (38,F)

3TC+ABC+ATV/r

56.7

55.9

 

910

176

C2 (45,M)

ZDV+3TC+SQV/r

88.4

75.1

 

730

230

C3 (26,F)

3TC+ABC+EFV

47

46.2

 

470

240

C4 (47,F)

TDF+FTC+LPV/r

84.6

80

 

1000

20

C5 (44,F)

ETV+ATV/r+RAL

94.7

80.4

 

530

42

C6 (42,M)

ZDV+FTC+EFV

55.8

50.3

 

430

80

C7 (39,F)

3TC+ABC+ATV/r

104

110.2

 

480

17

C8 (61,M)

TDF+FTC+EFV

134

78.5

 

530

340

C9 (42,F)

3TC+ABC+LPV/r

132

128.6

 

510

40

C10 (56,M)

ZDV+3TC+ABC

153.4

140.4

 

750

45

C11 (36,F)

3TC+ABC+LPV/r

100.4

93.1

 

700

200

C12 (43,M)

3TC+ABC+LPV/r

32.1

24.3

 

550

190

C13 (46,F)

TDF+FTC+EFV

83.6

71.9

 

330

40

C14 (37,F)

ZDV+3TC+LPV/r

62.3

58.3

 

720

140

Median

 

86.5

76.8

 

540**

110

  1. * Controls are denoted C1-C14
  2. ** CD4+ T-cell count differed between groups (p = 0.05)
  3. ABC, abakavir; ATV/r, atazanavir/ritonavir; EFV, efavirenz; ETV, entecavir; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; NVP, nevirapine; RAL, raltegravir; SQV/r, saquinavir/ritonavir; TDF, tenofovir; ZDV, zidovudine; 3TC, lamivudine;